CD8A and neoplasm: Patients with encapsulated lesions could benefit from antiangiogenic treatments already described41 and adoptive T‐cell therapies, since in dHGP CD8+ cells can reach tumor niches, less likely to be retained or excluded in the stroma by myeloid cells (siphoning).